RPTX (reparerx.com) Enterprise Value-to-Revenue Coefficient

Official company branding of Repare Therapeutics, Inc. (RPTX)

Repare Therapeutics (RPTX) leads the development of precision synthetic lethality-based therapies for oncology centers. Revenues are based on strategic alliances for the development of targeted drugs. The technology stack relies on robotic screening and cloud-based genomic analysis. The company's price-to-sales dynamics reflect market expectations, where the parameter value equals 166.81, helping investors balance their assets in a timely manner.

reparerx.com (RPTX): EV/Sales Multiple from 11/23/2025 to 02/07/2026

Financial and market metric breakdowns for Repare Therapeutics Inc. (RPTX)

- business market valuation indicators:
Fundamental company valuation:Repare Therapeutics RPTX
Product sample of reparerx.com

Repare Therapeutics' monopoly on DNA repair technologies and high FDA barriers create unique business value, which this indicator measures. By analyzing the EV/Sales multiple, an investor assesses the total enterprise value relative to revenue, allowing for a determination of the premium paid for future growth and the market consensus regarding the potential of targeted therapy.